[
  {
    "drug_id": 1,
    "name": "Osimertinib",
    "target_gene": "EGFR",
    "mutation_types": "T790M",
    "cancer_type": "Lung",
    "mechanism": "EFGR inhibitor",
    "ic50": 0.15,
    "confidence": 94,
    "side_effects": "rash, diarrhea, dry skin",
    "clinical_trial": "FLAURA Phase III",
    "approval_status": "FDA-approved",
    "description": "Third-gen EGFR inhibitor for T790M NSCLC. Targets mutant EGFR while sparing wild-type.",
    "clinical_evidence": "FLAURA Phase III showed improved survival in EGFR T790M NSCLC."
  },
  {
    "drug_id": 2,
    "name": "Olaparib",
    "target_gene": "BRCA1/2",
    "mutation_types": "Unknown mutation",
    "cancer_type": "Breast, Pancreatic",
    "mechanism": "PARP inhibitor",
    "ic50": 0.22,
    "confidence": 91,
    "side_effects": "fatigue, anemia",
    "clinical_trial": "OlympiAD Trial",
    "approval_status": "FDA-approved",
    "description": "PARP inhibitor for BRCA1/2 mutations. Blocks DNA repair in tumors.",
    "clinical_evidence": "OlympiAD trial showed efficacy in BRCA-mutated breast cancer."
  },
  {
    "drug_id": 3,
    "name": "Crizotinib",
    "target_gene": "ALK",
    "mutation_types": "ALK fusion",
    "cancer_type": "Lung",
    "mechanism": "ALK inhibitor",
    "ic50": 0.3,
    "confidence": 89,
    "side_effects": "nausea, visual disturbances",
    "clinical_trial": "PROFILE 1014",
    "approval_status": "FDA-approved",
    "description": "Inhibits ALK, ROS1, MET kinases. Used in ALK-positive NSCLC.",
    "clinical_evidence": "PROFILE 1014 improved PFS vs chemo in ALK+ lung cancer."
  },
  {
    "drug_id": 4,
    "name": "Trastuzumab",
    "target_gene": "HER2",
    "mutation_types": "Amplification",
    "cancer_type": "Breast",
    "mechanism": "HER2 monoclonal antibody",
    "ic50": 0.12,
    "confidence": 95,
    "side_effects": "cardiotoxicity",
    "clinical_trial": "EMILIA",
    "approval_status": "FDA-approved",
    "description": "HER2 antibody for HER2+ breast cancer. Inhibits growth & boosts immunity.",
    "clinical_evidence": "EMILIA trial showed benefit in HER2+ metastatic breast cancer."
  },
  {
    "drug_id": 5,
    "name": "Dabrafenib",
    "target_gene": "BRAF",
    "mutation_types": "V600E",
    "cancer_type": "Melanoma",
    "mechanism": "BRAF inhibitor",
    "ic50": 0.25,
    "confidence": 90,
    "side_effects": "hyperkeratosis, fever",
    "clinical_trial": "BREAK-3",
    "approval_status": "FDA-approved",
    "description": "BRAF V600E inhibitor for melanoma. Interrupts MAPK signaling pathway.",
    "clinical_evidence": "BREAK-3 trial improved response in V600E-mutant melanoma."
  },
  {
    "drug_id": 6,
    "name": "Vemurafenib",
    "target_gene": "BRAF",
    "mutation_types": "V600E",
    "cancer_type": "Melanoma",
    "mechanism": "BRAF inhibitor",
    "ic50": 0.33,
    "confidence": 88,
    "side_effects": "arthralgia, rash",
    "clinical_trial": "BRIM-3",
    "approval_status": "FDA-approved",
    "description": "Targets BRAF V600E mutations in melanoma. Inhibits abnormal cell growth.",
    "clinical_evidence": "BRIM-3 study showed improved survival in BRAF-mutated melanoma."
  },
  {
    "drug_id": 7,
    "name": "Nivolumab",
    "target_gene": "PD-1",
    "mutation_types": "Overexpression",
    "cancer_type": "Multiple",
    "mechanism": "Immune checkpoint inhibitor",
    "ic50": 1.2,
    "confidence": 93,
    "side_effects": "fatigue, colitis",
    "clinical_trial": "CHECKMATE-067",
    "approval_status": "FDA-approved",
    "description": "Boosts T-cell activity against tumors by blocking PD-1 receptors.",
    "clinical_evidence": "CheckMate-067 showed durable responses in melanoma and other cancers."
  },
  {
    "drug_id": 8,
    "name": "Pembrolizumab",
    "target_gene": "PD-1",
    "mutation_types": "Overexpression",
    "cancer_type": "Multiple",
    "mechanism": "Immune checkpoint inhibitor",
    "ic50": 1.1,
    "confidence": 92,
    "side_effects": "fever, rash, hypothyroidism",
    "clinical_trial": "KEYNOTE-001",
    "approval_status": "FDA-approved",
    "description": "Restores immune detection of cancer by blocking PD-1 on T-cells.",
    "clinical_evidence": "KEYNOTE-001 demonstrated effectiveness in PD-L1+ NSCLC patients."
  },
  {
    "drug_id": 9,
    "name": "Atezolizumab",
    "target_gene": "PD-L1",
    "mutation_types": "Overexpression",
    "cancer_type": "Lung, Bladder",
    "mechanism": "PD-L1 inhibitor",
    "ic50": 0.98,
    "confidence": 90,
    "side_effects": "fatigue, decreased appetite",
    "clinical_trial": "IMpower110",
    "approval_status": "FDA-approved",
    "description": "Inhibits PD-L1 to reactivate immune response against tumors.",
    "clinical_evidence": "IMpower110 improved overall survival in PD-L1+ lung cancer."
  },
  {
    "drug_id": 10,
    "name": "Enzalutamide",
    "target_gene": "AR",
    "mutation_types": "Overexpression",
    "cancer_type": "Prostate",
    "mechanism": "Androgen receptor antagonist",
    "ic50": 0.21,
    "confidence": 87,
    "side_effects": "headache, hot flashes",
    "clinical_trial": "PREVAIL",
    "approval_status": "FDA-approved",
    "description": "Blocks androgen receptor signaling to slow prostate cancer growth.",
    "clinical_evidence": "PREVAIL trial showed longer survival in metastatic prostate cancer."
  },
  {
    "drug_id": 11,
    "name": "Lapatinib",
    "target_gene": "HER2",
    "mutation_types": "Amplification",
    "cancer_type": "Breast",
    "mechanism": "Dual EGFR/HER2 inhibitor",
    "ic50": 0.45,
    "confidence": 86,
    "side_effects": "rash, diarrhea",
    "clinical_trial": "EGF100151",
    "approval_status": "FDA-approved",
    "description": "Blocks both HER2 and EGFR pathways in HER2+ breast cancers.",
    "clinical_evidence": "EGF100151 showed benefit when combined with capecitabine in HER2+ patients."
  },
  {
    "drug_id": 12,
    "name": "Sorafenib",
    "target_gene": "VEGFR",
    "mutation_types": "Unknown mutation",
    "cancer_type": "Kidney, Liver",
    "mechanism": "Multi-kinase inhibitor",
    "ic50": 0.6,
    "confidence": 84,
    "side_effects": "hand-foot syndrome, hypertension",
    "clinical_trial": "SHARP",
    "approval_status": "FDA-approved",
    "description": "Targets multiple kinases including VEGFR to block angiogenesis.",
    "clinical_evidence": "SHARP trial showed improved survival in liver cancer patients."
  },
  {
    "drug_id": 13,
    "name": "Erlotinib",
    "target_gene": "EGFR",
    "mutation_types": "L858r",
    "cancer_type": "Lung",
    "mechanism": "EFGR inhibitor",
    "ic50": 0.08,
    "confidence": 95,
    "side_effects": "rash, diarrhea",
    "clinical_trial": "BR.21",
    "approval_status": "FDA-approved",
    "description": "Inhibits EGFR signaling in tumors with activating mutations.",
    "clinical_evidence": "BR.21 showed survival benefit in advanced NSCLC patients."
  },
  {
    "drug_id": 14,
    "name": "Axitinib",
    "target_gene": "VEGFR",
    "mutation_types": "Unknown mutation",
    "cancer_type": "Kidney",
    "mechanism": "VEGFR inhibitor",
    "ic50": 0.19,
    "confidence": 85,
    "side_effects": "hypertension, fatigue",
    "clinical_trial": "AXIS",
    "approval_status": "FDA-approved",
    "description": "Blocks VEGF receptors to reduce tumor blood supply in renal cancer.",
    "clinical_evidence": "AXIS trial showed longer PFS than sorafenib in RCC."
  },
  {
    "drug_id": 15,
    "name": "Everolimus",
    "target_gene": "Mtor",
    "mutation_types": "Unknown mutation",
    "cancer_type": "Kidney, Breast",
    "mechanism": "Mtor INHIBITOR",
    "ic50": 0.55,
    "confidence": 83,
    "side_effects": "infections, stomatitis",
    "clinical_trial": "RECORD-1",
    "approval_status": "FDA-approved",
    "description": "Inhibits mTOR pathway to block tumor cell proliferation and growth.",
    "clinical_evidence": "RECORD-1 trial improved PFS in advanced RCC after VEGF therapy."
  },
  {
    "drug_id": 16,
    "name": "Ibrutinib",
    "target_gene": "BTK",
    "mutation_types": "BTK mutation",
    "cancer_type": "Leukemia",
    "mechanism": "BTK inhibitor",
    "ic50": 0.11,
    "confidence": 91,
    "side_effects": "bleeding, infections",
    "clinical_trial": "RESONATE",
    "approval_status": "FDA-approved",
    "description": "A BTK inhibitor that blocks B-cell receptor signaling in malignant B cells. Used in chronic lymphocytic leukemia (CLL).",
    "clinical_evidence": "RESONATE trial showed improved progression-free survival in relapsed/refractory CLL."
  },
  {
    "drug_id": 17,
    "name": "Idelalisib",
    "target_gene": "PI3K?",
    "mutation_types": "Unknown mutation",
    "cancer_type": "Lymphoma",
    "mechanism": "PI3K delta inhibitor",
    "ic50": 0.2,
    "confidence": 88,
    "side_effects": "diarrhea, hepatotoxicity",
    "clinical_trial": "ZETA",
    "approval_status": "FDA-approved",
    "description": "Targets PI3Kδ, disrupting signaling pathways critical for B-cell survival. Used for follicular lymphoma and CLL.",
    "clinical_evidence": "ZETA trial demonstrated durable responses in relapsed follicular lymphoma."
  },
  {
    "drug_id": 18,
    "name": "Venetoclax",
    "target_gene": "BCL-2",
    "mutation_types": "Overexpression",
    "cancer_type": "Leukemia",
    "mechanism": "BCL-2 inhibitor",
    "ic50": 0.13,
    "confidence": 92,
    "side_effects": "neutropenia, nausea",
    "clinical_trial": "M14-032",
    "approval_status": "FDA-approved",
    "description": "BCL-2 inhibitor promoting apoptosis in leukemia cells. Primarily used for CLL and AML.",
    "clinical_evidence": "M14-032 trial showed high response rate in CLL patients with 17p deletion."
  },
  {
    "drug_id": 19,
    "name": "Cabozantinib",
    "target_gene": "MET",
    "mutation_types": "MET exon 14 skip",
    "cancer_type": "Thyroid, Kidney",
    "mechanism": "Multi-kinase inhibitor",
    "ic50": 0.27,
    "confidence": 89,
    "side_effects": "diarrhea, fatigue",
    "clinical_trial": "EXAM",
    "approval_status": "FDA-approved",
    "description": "Multi-kinase inhibitor that blocks MET, VEGFR, and RET pathways. Effective in thyroid and renal cancers.",
    "clinical_evidence": "EXAM trial showed improved PFS in medullary thyroid carcinoma."
  },
   {
    "drug_id": 20,
    "name": "Capmatinib",
    "target_gene": "MET",
    "mutation_types": "MET exon 14 skip",
    "cancer_type": "NSCLC, Hepatocellular Carcinoma",
    "mechanism": "Selective MET inhibitor",
    "ic50": 0.13,
    "confidence": 92,
    "side_effects": "peripheral edema, nausea, creatinine increase",
    "clinical_trial": "GEOMETRY mono‑1",
    "approval_status": "FDA‑approved",
    "description": "Selective MET inhibitor for MET exon 14 altered NSCLC. Reduces MET signaling and tumor growth.",
    "clinical_evidence": "GEOMETRY mono-1 trial showed positive response in MET-altered NSCLC patients."
  },
  {
    "drug_id": 21,
    "name": "Tepotinib",
    "target_gene": "MET",
    "mutation_types": "MET exon 14 skip",
    "cancer_type": "NSCLC",
    "mechanism": "Selective MET inhibitor",
    "ic50": 0.37,
    "confidence": 90,
    "side_effects": "edema, nausea, fatigue, diarrhea",
    "clinical_trial": "VISION",
    "approval_status": "FDA‑approved",
    "description": "Highly selective MET inhibitor used in NSCLC with MET exon 14 skipping mutations.",
    "clinical_evidence": "VISION trial demonstrated durable responses and manageable safety profile."
  },
  {
    "drug_id": 22,
    "name": "Crizotinib",
    "target_gene": "MET",
    "mutation_types": "MET exon 14 skip",
    "cancer_type": "NSCLC",
    "mechanism": "ALK/MET/ROS1 TKI",
    "ic50": 5.0,
    "confidence": 85,
    "side_effects": "edema, visual impairment, nausea, diarrhea",
    "clinical_trial": "PROFILE series",
    "approval_status": "FDA‑approved",
    "description": "Inhibits ALK, ROS1, and MET tyrosine kinases. Approved for ALK-positive NSCLC.",
    "clinical_evidence": "PROFILE series established efficacy in ALK-positive NSCLC with MET activity noted."
  },
  {
    "drug_id": 23,
    "name": "Savolitinib",
    "target_gene": "MET",
    "mutation_types": "MET exon 14 skip, MET amplification",
    "cancer_type": "NSCLC, Lung Sarcomatoid",
    "mechanism": "Selective MET inhibitor",
    "ic50": 0.5,
    "confidence": 88,
    "side_effects": "nausea, peripheral edema, increased ALT/AST",
    "clinical_trial": "TATTON",
    "approval_status": "Approved in China",
    "description": "Selective MET inhibitor showing promise in MET-amplified NSCLC and lung sarcomatoid carcinoma.",
    "clinical_evidence": "TATTON trial showed significant tumor shrinkage in MET-altered lung cancers."
  },
  {
    "drug_id": 24,
    "name": "Merestinib",
    "target_gene": "MET",
    "mutation_types": "MET exon 14 skip",
    "cancer_type": "NSCLC",
    "mechanism": "Type II MET/RON inhibitor",
    "ic50": 2.0,
    "confidence": 78,
    "side_effects": "peripheral edema, nausea",
    "clinical_trial": "Phase II (NCT02920996)",
    "approval_status": "Investigational",
    "description": "Type II MET inhibitor that binds inactive conformation. Being investigated for MET-altered NSCLC.",
    "clinical_evidence": "Phase II NCT02920996 indicated partial responses in MET-altered tumors."
  },
  {
    "drug_id": 25,
    "name": "Foretinib",
    "target_gene": "MET",
    "mutation_types": "MET exon 14 skip, D1228X, Y1230X",
    "cancer_type": "NSCLC",
    "mechanism": "Type II MET inhibitor",
    "ic50": 3.1,
    "confidence": 75,
    "side_effects": "fatigue, hypertension",
    "clinical_trial": "Resistance studies",
    "approval_status": "Investigational",
    "description": "Targets multiple MET alterations including D1228X/Y1230X. Aims to overcome resistance to earlier MET TKIs.",
    "clinical_evidence": "Resistance studies suggest activity in MET-TKI-resistant NSCLC."
  },
  {
    "drug_id": 26,
    "name": "Glesatinib",
    "target_gene": "MET",
    "mutation_types": "MET exon 14 skip",
    "cancer_type": "NSCLC",
    "mechanism": "Multi‑target MET/VEGFR inhibitor",
    "ic50": 2.8,
    "confidence": 80,
    "side_effects": "edema, hypertension",
    "clinical_trial": "Preclinical/early phase",
    "approval_status": "Investigational",
    "description": "Dual MET and VEGFR2 inhibitor under investigation for NSCLC. Shows anti-angiogenic and MET blockade effects.",
    "clinical_evidence": "Early-phase trials suggest tolerability and preliminary efficacy."
  },
  {
    "drug_id": 27,
    "name": "Erlotinib",
    "target_gene": "EGFR",
    "mutation_types": "EGFR exon 19 del; L858R",
    "cancer_type": "NSCLC, Pancreatic",
    "mechanism": "EGFR TKI",
    "ic50": 0.019,
    "confidence": 90,
    "side_effects": "rash, diarrhea, muscle/joint pain",
    "clinical_trial": "BR.21",
    "approval_status": "FDA‑approved",
    "description": "EGFR inhibitor that blocks tumor cell proliferation. Used for NSCLC and pancreatic cancers.",
    "clinical_evidence": "BR.21 trial demonstrated survival benefit in advanced NSCLC patients."
  },
  {
    "drug_id": 28,
    "name": "Amivantamab",
    "target_gene": "EGFR, MET",
    "mutation_types": "EGFR exon 20 ins",
    "cancer_type": "NSCLC",
    "mechanism": "Bispecific mAb",
    "ic50": null,
    "confidence": 89,
    "side_effects": "rash, infusion reactions, rash, fatigue",
    "clinical_trial": "CHRYSALIS",
    "approval_status": "FDA‑approved",
    "description": "Bispecific antibody targeting EGFR and MET alterations. Effective in exon 20 insertions.",
    "clinical_evidence": "CHRYSALIS trial showed response in EGFR exon 20 insertion-positive NSCLC."
  },
  {
    "drug_id": 29,
    "name": "Axitinib",
    "target_gene": "VEGFR1/2/3, c‑KIT, PDGFR",
    "mutation_types": "N/A",
    "cancer_type": "Renal Cell Carcinoma",
    "mechanism": "VEGFR TKI",
    "ic50": 0.1,
    "confidence": 88,
    "side_effects": "diarrhea, hypertension, fatigue, hand‑foot syndrome",
    "clinical_trial": "AXIS",
    "approval_status": "FDA‑approved",
    "description": "Potent VEGFR inhibitor for advanced RCC. Reduces angiogenesis and tumor growth.",
    "clinical_evidence": "AXIS trial confirmed improved progression-free survival in RCC."
  },
  {
    "drug_id": 30,
    "name": "Asciminib",
    "target_gene": "ABL1",
    "mutation_types": "BCR‑ABL1 T315I",
    "cancer_type": "CML",
    "mechanism": "STAMP inhibitor",
    "ic50": 0.005,
    "confidence": 90,
    "side_effects": "fatigue, musculoskeletal pain, rash, diarrhea",
    "clinical_trial": "ASCEMBL",
    "approval_status": "FDA‑approved",
    "description": "STAMP inhibitor selectively targeting ABL1. Used in resistant CML mutations like T315I.",
    "clinical_evidence": "ASCEMBL trial showed superior efficacy over bosutinib in CML patients."
  },
  {
    "drug_id": 31,
    "name": "Alectinib",
    "target_gene": "ALK",
    "mutation_types": "EML4-ALK fusion",
    "cancer_type": "NSCLC",
    "mechanism": "ALK inhibitor",
    "ic50": 0.01,
    "confidence": 93,
    "side_effects": "fatigue, constipation, edema, rash",
    "clinical_trial": "ALEX",
    "approval_status": "FDA-approved",
    "description": "Second-gen ALK inhibitor effective in ALK+ NSCLC. Crosses blood-brain barrier.",
    "clinical_evidence": "ALEX trial showed significant PFS in ALK-positive NSCLC."
  },
  {
    "drug_id": 32,
    "name": "Lorlatinib",
    "target_gene": "ALK, ROS1",
    "mutation_types": "ALK fusions, ALK G1202R",
    "cancer_type": "NSCLC",
    "mechanism": "3rd-gen ALK/ROS1 TKI",
    "ic50": 0.02,
    "confidence": 91,
    "side_effects": "hypercholesterolemia, edema, weight gain",
    "clinical_trial": "CROWN",
    "approval_status": "FDA-approved",
    "description": "3rd-gen ALK/ROS1 inhibitor. Targets resistant mutations including G1202R.",
    "clinical_evidence": "CROWN study showed superior outcomes vs crizotinib in ALK+ NSCLC."
  },
  {
    "drug_id": 33,
    "name": "Entrectinib",
    "target_gene": "ROS1, NTRK, ALK",
    "mutation_types": "ROS1 fusion, NTRK1/2/3 fusion",
    "cancer_type": "NSCLC, NTRK fusion-positive cancers",
    "mechanism": "Pan-TRK/ROS1/ALK inhibitor",
    "ic50": 0.02,
    "confidence": 89,
    "side_effects": "dizziness, fatigue, weight gain, taste changes",
    "clinical_trial": "STARTRK‑2",
    "approval_status": "FDA-approved",
    "description": "Pan-TRK/ROS1/ALK inhibitor for fusion-positive cancers. CNS-active profile.",
    "clinical_evidence": "STARTRK-2 trial demonstrated durable responses across multiple cancers."
  },
  {
    "drug_id": 34,
    "name": "Dabrafenib",
    "target_gene": "BRAF",
    "mutation_types": "BRAF V600E",
    "cancer_type": "Melanoma, NSCLC",
    "mechanism": "BRAF inhibitor",
    "ic50": 0.006,
    "confidence": 92,
    "side_effects": "hyperkeratosis, fever, joint pain",
    "clinical_trial": "BREAK‑3",
    "approval_status": "FDA-approved",
    "description": "Selective BRAF V600E inhibitor used in melanoma and NSCLC. Often used in combination.",
    "clinical_evidence": "BREAK-3 trial validated its efficacy in BRAF V600E+ melanoma."
  },
  {
    "drug_id": 35,
    "name": "Trametinib",
    "target_gene": "MEK1/2",
    "mutation_types": "BRAF V600E (used in combo)",
    "cancer_type": "Melanoma, NSCLC",
    "mechanism": "MEK inhibitor",
    "ic50": 0.05,
    "confidence": 90,
    "side_effects": "rash, diarrhea, hypertension",
    "clinical_trial": "COMBI‑d",
    "approval_status": "FDA-approved",
    "description": "MEK1/2 inhibitor used in BRAF-mutant cancers. Slows MAPK pathway signaling.",
    "clinical_evidence": "COMBI-d trial proved benefit when combined with dabrafenib."
  },
  {
    "drug_id": 36,
    "name": "Vemurafenib",
    "target_gene": "BRAF",
    "mutation_types": "BRAF V600E",
    "cancer_type": "Melanoma, Erdheim–Chester disease",
    "mechanism": "BRAF inhibitor",
    "ic50": 0.031,
    "confidence": 88,
    "side_effects": "arthralgia, rash, fatigue, alopecia",
    "clinical_trial": "BRIM‑3",
    "approval_status": "FDA-approved",
    "description": "BRAF inhibitor targeting V600E mutations. Used in melanoma and rare histologies.",
    "clinical_evidence": "BRIM-3 trial showed improved survival in BRAF-mutant melanoma."
  },
  {
    "drug_id": 37,
    "name": "Neratinib",
    "target_gene": "HER2 (ERBB2)",
    "mutation_types": "HER2 overexpression, HER2 mutations",
    "cancer_type": "Breast, NSCLC",
    "mechanism": "Pan-HER irreversible inhibitor",
    "ic50": 0.02,
    "confidence": 86,
    "side_effects": "diarrhea, nausea, vomiting",
    "clinical_trial": "ExteNET",
    "approval_status": "FDA-approved",
    "description": "Irreversible pan-HER TKI used post-HER2 therapy. Reduces recurrence in HER2+ cancers.",
    "clinical_evidence": "ExteNET trial showed benefit in extended adjuvant therapy for breast cancer."
  },
  {
    "drug_id": 38,
    "name": "Lapatinib",
    "target_gene": "HER2, EGFR",
    "mutation_types": "HER2 overexpression",
    "cancer_type": "Breast",
    "mechanism": "HER2/EGFR dual TKI",
    "ic50": 0.008,
    "confidence": 84,
    "side_effects": "diarrhea, rash, fatigue",
    "clinical_trial": "EGF100151",
    "approval_status": "FDA-approved",
    "description": "Targets both HER2 and EGFR receptors to suppress tumor growth.",
    "clinical_evidence": "EGF100151 trial showed Lapatinib delayed progression in HER2+ breast cancer."
  },
  {
    "drug_id": 39,
    "name": "Selpercatinib",
    "target_gene": "RET",
    "mutation_types": "RET fusion, RET mutation",
    "cancer_type": "Thyroid, NSCLC",
    "mechanism": "Selective RET inhibitor",
    "ic50": 0.001,
    "confidence": 94,
    "side_effects": "hypertension, dry mouth, constipation",
    "clinical_trial": "LIBRETTO‑001",
    "approval_status": "FDA-approved",
    "description": "Highly selective RET kinase inhibitor for fusion-positive cancers.",
    "clinical_evidence": "LIBRETTO-001 demonstrated durable responses in RET-driven cancers."
  },
  {
    "drug_id": 40,
    "name": "Pralsetinib",
    "target_gene": "RET",
    "mutation_types": "RET fusion, RET mutation",
    "cancer_type": "Thyroid, NSCLC",
    "mechanism": "Selective RET inhibitor",
    "ic50": 0.003,
    "confidence": 91,
    "side_effects": "anemia, constipation, increased liver enzymes",
    "clinical_trial": "ARROW",
    "approval_status": "FDA-approved",
    "description": "Targets RET alterations in thyroid and lung cancers.",
    "clinical_evidence": "ARROW trial showed high response rates in RET fusion-positive tumors."
  },
   {
    "drug_id": 41,
    "name": "Imatinib",
    "target_gene": "BCR-ABL, KIT, PDGFR",
    "mutation_types": "BCR-ABL fusion, KIT exon 11",
    "cancer_type": "CML, GIST",
    "mechanism": "Tyrosine kinase inhibitor",
    "ic50": 0.58,
    "confidence": 95,
    "side_effects": "nausea, muscle cramps, edema",
    "clinical_trial": "IRIS",
    "approval_status": "FDA-approved",
    "description": "Pioneering TKI that inhibits BCR-ABL and other kinases.",
    "clinical_evidence": "IRIS trial confirmed long-term survival in CML patients on Imatinib."
  },
  {
    "drug_id": 42,
    "name": "Nilotinib",
    "target_gene": "BCR-ABL",
    "mutation_types": "BCR-ABL T315I-resistant",
    "cancer_type": "CML",
    "mechanism": "2nd-gen BCR-ABL inhibitor",
    "ic50": 0.28,
    "confidence": 91,
    "side_effects": "rash, headache, elevated lipase",
    "clinical_trial": "ENESTnd",
    "approval_status": "FDA-approved",
    "description": "Next-gen ABL inhibitor designed for resistant CML mutations.",
    "clinical_evidence": "ENESTnd showed faster response and deeper remission vs. Imatinib."
  },
  {
    "drug_id": 43,
    "name": "Dasatinib",
    "target_gene": "BCR-ABL, SRC",
    "mutation_types": "BCR-ABL fusion, T315I",
    "cancer_type": "CML, Ph+ ALL",
    "mechanism": "Multi-target tyrosine kinase inhibitor",
    "ic50": 0.5,
    "confidence": 92,
    "side_effects": "pleural effusion, headache, fatigue",
    "clinical_trial": "DASISION",
    "approval_status": "FDA-approved",
    "description": "Broad-spectrum TKI used in Ph+ leukemias.",
    "clinical_evidence": "DASISION trial showed superior outcomes to Imatinib in CML."
  },
  {
    "drug_id": 44,
    "name": "Ponatinib",
    "target_gene": "BCR-ABL (T315I)",
    "mutation_types": "T315I mutation",
    "cancer_type": "CML, Ph+ ALL",
    "mechanism": "3rd-gen BCR-ABL inhibitor",
    "ic50": 0.08,
    "confidence": 94,
    "side_effects": "hypertension, rash, arterial thrombosis",
    "clinical_trial": "PACE",
    "approval_status": "FDA-approved",
    "description": "Effective against T315I mutant CML cases.",
    "clinical_evidence": "PACE trial demonstrated activity in resistant CML and ALL."
  },
  {
    "drug_id": 45,
    "name": "Ivosidenib",
    "target_gene": "IDH1",
    "mutation_types": "IDH1 R132H",
    "cancer_type": "AML, Cholangiocarcinoma",
    "mechanism": "IDH1 inhibitor",
    "ic50": 0.07,
    "confidence": 90,
    "side_effects": "fatigue, leukocytosis, QT prolongation",
    "clinical_trial": "AG120-C-001",
    "approval_status": "FDA-approved",
    "description": "Selective inhibitor targeting mutant IDH1 enzyme.",
    "clinical_evidence": "AG120-C-001 showed remission in IDH1-mutated AML."
  },
  {
    "drug_id": 46,
    "name": "Enasidenib",
    "target_gene": "IDH2",
    "mutation_types": "IDH2 R140Q",
    "cancer_type": "AML",
    "mechanism": "IDH2 inhibitor",
    "ic50": 0.05,
    "confidence": 89,
    "side_effects": "nausea, differentiation syndrome, elevated bilirubin",
    "clinical_trial": "AG221-C-001",
    "approval_status": "FDA-approved",
    "description": "IDH2 inhibitor reducing oncometabolite 2-HG in AML.",
    "clinical_evidence": "AG221-C-001 led to hematologic improvements in relapsed AML."
  },
  {
    "drug_id": 47,
    "name": "Talazoparib",
    "target_gene": "PARP1/2",
    "mutation_types": "BRCA1/2 mutations",
    "cancer_type": "Breast, Prostate",
    "mechanism": "PARP inhibitor",
    "ic50": 0.57,
    "confidence": 90,
    "side_effects": "fatigue, anemia, nausea",
    "clinical_trial": "EMBRACA",
    "approval_status": "FDA-approved",
    "description": "Potent PARP1/2 inhibitor for BRCA-mutated tumors.",
    "clinical_evidence": "EMBRACA trial showed improved progression-free survival."
  },
  {
    "drug_id": 48,
    "name": "Rucaparib",
    "target_gene": "PARP1/2",
    "mutation_types": "BRCA1/2 mutations",
    "cancer_type": "Ovarian, Prostate",
    "mechanism": "PARP inhibitor",
    "ic50": 0.19,
    "confidence": 88,
    "side_effects": "nausea, fatigue, increased ALT/AST",
    "clinical_trial": "ARIEL3",
    "approval_status": "FDA-approved",
    "description": "Inhibits DNA repair enzymes PARP1/2 in tumors with HRD.",
    "clinical_evidence": "ARIEL3 supported FDA approval in recurrent ovarian cancer."
  },
  {
    "drug_id": 49,
    "name": "Olaparib",
    "target_gene": "PARP1/2",
    "mutation_types": "BRCA1/2 mutations",
    "cancer_type": "Breast, Ovarian, Pancreatic, Prostate",
    "mechanism": "PARP inhibitor",
    "ic50": 0.09,
    "confidence": 95,
    "side_effects": "nausea, fatigue, anemia",
    "clinical_trial": "SOLO1, PROfound",
    "approval_status": "FDA-approved",
    "description": "Targets DNA repair via PARP inhibition in BRCA-mutated tumors. Improves progression-free survival.",
    "clinical_evidence": "SOLO1 and PROfound trials demonstrated significant benefit in BRCA-mutated ovarian and prostate cancers."
  },
  {
    "drug_id": 50,
    "name": "Veliparib",
    "target_gene": "PARP1/2",
    "mutation_types": "BRCA1/2 mutations",
    "cancer_type": "Ovarian, Breast",
    "mechanism": "PARP inhibitor",
    "ic50": 0.63,
    "confidence": 85,
    "side_effects": "nausea, fatigue, neutropenia",
    "clinical_trial": "BROCADE3",
    "approval_status": "Investigational",
    "description": "Investigational PARP inhibitor under study for BRCA-mutated cancers. Disrupts DNA repair.",
    "clinical_evidence": "BROCADE3 trial showed improved PFS in combination therapy for BRCA-mutated breast cancer."
  },
  {
    "drug_id": 51,
    "name": "Nivolumab",
    "target_gene": "PD-1",
    "mutation_types": "High PD-L1 expression, MSI-H/dMMR",
    "cancer_type": "Melanoma, NSCLC, RCC, Hodgkin lymphoma",
    "mechanism": "PD-1 immune checkpoint inhibitor",
    "ic50": 0.12,
    "confidence": 97,
    "side_effects": "fatigue, rash, immune-related toxicities",
    "clinical_trial": "CheckMate series",
    "approval_status": "FDA-approved",
    "description": "Immune checkpoint inhibitor blocking PD-1 pathway. Restores T-cell anti-tumor activity.",
    "clinical_evidence": "CheckMate trials showed durable responses in NSCLC, RCC, melanoma, and Hodgkin lymphoma."
  },
  {
    "drug_id": 52,
    "name": "Pembrolizumab",
    "target_gene": "PD-1",
    "mutation_types": "MSI-H, dMMR, PD-L1+",
    "cancer_type": "Melanoma, NSCLC, Endometrial, HNSCC",
    "mechanism": "PD-1 immune checkpoint inhibitor",
    "ic50": 0.15,
    "confidence": 98,
    "side_effects": "colitis, pneumonitis, thyroiditis",
    "clinical_trial": "KEYNOTE series",
    "approval_status": "FDA-approved",
    "description": "Blocks PD-1 to enable immune attack on tumors. FDA-approved for multiple solid cancers.",
    "clinical_evidence": "KEYNOTE studies confirmed high efficacy in MSI-H, PD-L1+, and dMMR tumors."
  },
  {
    "drug_id": 53,
    "name": "Atezolizumab",
    "target_gene": "PD-L1",
    "mutation_types": "High PD-L1 expression",
    "cancer_type": "NSCLC, Bladder cancer",
    "mechanism": "PD-L1 immune checkpoint inhibitor",
    "ic50": 0.14,
    "confidence": 94,
    "side_effects": "fatigue, decreased appetite, immune toxicities",
    "clinical_trial": "IMpower series",
    "approval_status": "FDA-approved",
    "description": "Blocks PD-L1 to reactivate immune response against tumors. Used in bladder and lung cancer.",
    "clinical_evidence": "IMpower trials demonstrated OS benefits in PD-L1+ NSCLC and urothelial cancers."
  },
  {
    "drug_id": 54,
    "name": "Durvalumab",
    "target_gene": "PD-L1",
    "mutation_types": "PD-L1 overexpression",
    "cancer_type": "NSCLC, Bladder, Liver cancer",
    "mechanism": "PD-L1 immune checkpoint inhibitor",
    "ic50": 0.16,
    "confidence": 93,
    "side_effects": "cough, pneumonitis, rash",
    "clinical_trial": "PACIFIC",
    "approval_status": "FDA-approved",
    "description": "Checkpoint inhibitor targeting PD-L1. Enhances T-cell-mediated tumor killing.",
    "clinical_evidence": "PACIFIC trial improved survival as consolidation therapy in NSCLC post-chemoradiation."
  },
  {
    "drug_id": 55,
    "name": "Ipilimumab",
    "target_gene": "CTLA-4",
    "mutation_types": "N/A",
    "cancer_type": "Melanoma, RCC, CRC (with MSI-H)",
    "mechanism": "CTLA-4 immune checkpoint inhibitor",
    "ic50": 0.22,
    "confidence": 91,
    "side_effects": "colitis, rash, immune hepatitis",
    "clinical_trial": "CA184-029",
    "approval_status": "FDA-approved",
    "description": "CTLA-4 checkpoint inhibitor enhancing early T-cell activation. Effective in melanoma.",
    "clinical_evidence": "CA184-029 trial confirmed OS benefits in advanced melanoma as monotherapy."
  },
  {
    "drug_id": 56,
    "name": "Sacituzumab govitecan",
    "target_gene": "TROP-2",
    "mutation_types": "TROP-2 overexpression",
    "cancer_type": "Triple-negative breast cancer, Bladder",
    "mechanism": "Antibody-drug conjugate",
    "ic50": 0.3,
    "confidence": 92,
    "side_effects": "neutropenia, diarrhea, nausea",
    "clinical_trial": "ASCENT",
    "approval_status": "FDA-approved",
    "description": "Antibody-drug conjugate targeting TROP-2. Delivers cytotoxic payload to cancer cells.",
    "clinical_evidence": "ASCENT trial showed improved PFS and OS in triple-negative breast cancer."
  },
  {
    "drug_id": 57,
    "name": "Trastuzumab deruxtecan",
    "target_gene": "HER2",
    "mutation_types": "HER2-low, HER2+",
    "cancer_type": "Breast, Gastric",
    "mechanism": "HER2-targeted antibody-drug conjugate",
    "ic50": 0.04,
    "confidence": 95,
    "side_effects": "interstitial lung disease, nausea, fatigue",
    "clinical_trial": "DESTINY-Breast03",
    "approval_status": "FDA-approved",
    "description": "HER2-directed antibody-drug conjugate with topoisomerase payload. Works in HER2-low tumors.",
    "clinical_evidence": "DESTINY-Breast03 showed superior PFS over trastuzumab emtansine in HER2+ breast cancer."
  },
  {
    "drug_id": 58,
    "name": "Belantamab mafodotin",
    "target_gene": "BCMA",
    "mutation_types": "BCMA expression",
    "cancer_type": "Multiple Myeloma",
    "mechanism": "BCMA-targeted antibody-drug conjugate",
    "ic50": 0.19,
    "confidence": 90,
    "side_effects": "ocular toxicity, thrombocytopenia",
    "clinical_trial": "DREAMM-2",
    "approval_status": "FDA-approved",
    "description": "Targets BCMA with cytotoxic conjugate for refractory myeloma. First-in-class ADC.",
    "clinical_evidence": "DREAMM-2 trial led to accelerated approval in relapsed/refractory multiple myeloma."
  },
  {
    "drug_id": 59,
    "name": "Tisotumab vedotin",
    "target_gene": "Tissue Factor (TF)",
    "mutation_types": "TF expression",
    "cancer_type": "Cervical cancer",
    "mechanism": "Antibody-drug conjugate",
    "ic50": 0.21,
    "confidence": 89,
    "side_effects": "eye toxicity, bleeding, fatigue",
    "clinical_trial": "innovaTV 204",
    "approval_status": "FDA-approved",
    "description": "Targets tissue factor in cervical cancer via ADC mechanism. Promotes tumor cell death.",
    "clinical_evidence": "innovaTV 204 trial showed high response rates in metastatic cervical cancer."
  },
  {
    "drug_id": 60,
    "name": "Zanubrutinib",
    "target_gene": "BTK",
    "mutation_types": "BTK C481S, WT",
    "cancer_type": "CLL, Waldenström’s macroglobulinemia",
    "mechanism": "BTK inhibitor",
    "ic50": 0.12,
    "confidence": 90,
    "side_effects": "neutropenia, pneumonia, hemorrhage",
    "clinical_trial": "ASPEN",
    "approval_status": "FDA-approved",
    "description": "Second-generation BTK inhibitor with improved selectivity. Used in B-cell malignancies.",
    "clinical_evidence": "ASPEN trial showed efficacy and better safety profile over ibrutinib in WM patients."
  }
]